Drugs / Elironrasib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05462717 | Sep 2022 → Mar 2027 expected | colorectal carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07397338 | Jan 2026 → May 2029 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06162221 | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06128551 | Nov 2023 → Dec 2028 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elironrasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128551 ↗ |
| Known as | RMC-6291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162221 ↗ |
| Action | Inhibit | “RMC-6291 (KRAS G12C(ON) inhibitor)” NCT05462717 ↗ |
| Modality | Small molecule | “We designed a natural product-inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for...” PMID 37590355 ↗ Aug 2023 |
| Route | Oral | “Oral tablet once or twice a day” NCT05462717 ↗ |
| Target | KRAS | “RMC-6291 (KRAS G12C(ON) inhibitor)” NCT05462717 ↗ |